|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UHRF1BP1 |
Gene summary for UHRF1BP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UHRF1BP1 | Gene ID | 54887 |
| Gene name | UHRF1 binding protein 1 | |
| Gene Alias | C6orf107 | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q6BDS2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54887 | UHRF1BP1 | HCC1_Meng | Human | Liver | HCC | 2.71e-47 | 1.14e-01 | 0.0246 |
| 54887 | UHRF1BP1 | HCC1 | Human | Liver | HCC | 1.14e-17 | 3.13e+00 | 0.5336 |
| 54887 | UHRF1BP1 | HCC2 | Human | Liver | HCC | 3.55e-11 | 2.83e+00 | 0.5341 |
| 54887 | UHRF1BP1 | HCC5 | Human | Liver | HCC | 2.44e-07 | 2.35e+00 | 0.4932 |
| 54887 | UHRF1BP1 | S014 | Human | Liver | HCC | 8.20e-04 | 3.13e-01 | 0.2254 |
| 54887 | UHRF1BP1 | S015 | Human | Liver | HCC | 5.07e-05 | 3.43e-01 | 0.2375 |
| 54887 | UHRF1BP1 | S016 | Human | Liver | HCC | 8.51e-04 | 2.95e-01 | 0.2243 |
| 54887 | UHRF1BP1 | S027 | Human | Liver | HCC | 5.19e-04 | 4.61e-01 | 0.2446 |
| 54887 | UHRF1BP1 | S028 | Human | Liver | HCC | 3.48e-14 | 5.54e-01 | 0.2503 |
| 54887 | UHRF1BP1 | S029 | Human | Liver | HCC | 1.33e-07 | 4.72e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UHRF1BP1 | SNV | Missense_Mutation | rs757764368 | c.494N>A | p.Arg165His | p.R165H | Q6BDS2 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| UHRF1BP1 | SNV | Missense_Mutation | novel | c.2496C>G | p.His832Gln | p.H832Q | Q6BDS2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| UHRF1BP1 | SNV | Missense_Mutation | c.2197N>T | p.Arg733Cys | p.R733C | Q6BDS2 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| UHRF1BP1 | SNV | Missense_Mutation | c.3205N>T | p.Pro1069Ser | p.P1069S | Q6BDS2 | protein_coding | tolerated(0.16) | benign(0.131) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UHRF1BP1 | SNV | Missense_Mutation | novel | c.1280G>A | p.Arg427Gln | p.R427Q | Q6BDS2 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| UHRF1BP1 | SNV | Missense_Mutation | novel | c.3005N>C | p.Val1002Ala | p.V1002A | Q6BDS2 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-D8-A73X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| UHRF1BP1 | SNV | Missense_Mutation | c.1273N>G | p.Leu425Val | p.L425V | Q6BDS2 | protein_coding | tolerated(0.16) | benign(0) | TCGA-GM-A5PX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
| UHRF1BP1 | SNV | Missense_Mutation | novel | c.818N>T | p.Ser273Ile | p.S273I | Q6BDS2 | protein_coding | deleterious(0) | benign(0.44) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| UHRF1BP1 | insertion | Frame_Shift_Ins | novel | c.2179_2180insCTCCCTGCCAGCTG | p.Trp727SerfsTer29 | p.W727Sfs*29 | Q6BDS2 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| UHRF1BP1 | insertion | In_Frame_Ins | novel | c.2632_2633insTTTTTC | p.Ala878delinsValPhePro | p.A878delinsVFP | Q6BDS2 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |